Crossmark

Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis

Crossref DOI link: https://doi.org/10.1186/s12885-019-5569-5

Published Online: 2019-04-15

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vickers, Adrian D. https://orcid.org/0000-0003-0304-1951
Winfree, Katherine B.

Cuyun Carter, Gebra

Kiiskinen, Urpo

Jen, Min-Hua

Stull, Donald

Kaye, James A.

Carbone, David P.
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2019-04-15
More Information

Article History

Received: 20 December 2017

Accepted: 2 April 2019

First Online: 15 April 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: ADV, DS and JAK are full-time employees of RTI Health Solutions, which received funding from Eli Lilly and Company to conduct this study. As salaried employees, they receive no payment or honoraria directly from Eli Lilly and Company for services rendered. The contract between RTI Health Solutions and the sponsor includes independent publication rights. RTI Health Solutions conducts work for government and private organizations, including pharmaceutical companies. KBW, GCC, UK and M-HJ are employees of Eli Lilly and Company. DPC did not receive any funding from Eli Lilly and Company related to this study.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.